Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of gastrointestinal (GI)products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation.
